About US
Contact us
-
Sanofi recalls 9 lots of Genzyme transplant drugGenzyme is pulling 9 lots of its kidney transplant drug Thymoglobulin after one lot failed a stability test. The company, which is Sanofi's ($SNY) U.S.-based rare disease division, pulled all lots2012/8/29
-
Lilly's Effient hopes dashed by head-to-head Plavix trialIt's another R&D stumble for Eli Lilly ($LLY). The clotbusting drug Effient, one of its newer products, failed to come through in a head-to-head study against Plavix. The trial, which tested the t2012/8/28
-
Take a gander at Glaxo's up-and-coming Philly buildingGlaxoSmithKline ($GSK) got a lot of local kudos when it inked a deal to relocate its Philadelphia offices to a brand-spanking-new building at the Navy Yard. City officials have been trying to develo2012/8/28
-
New Roche breast cancer drug delivers overall survival resultsRoche's ($RHHBY) experimental breast cancer drug T-DM1 hit another study target, prompting analysts to predict regulatory approval during the first half of next year. After showing it can hold off tum2012/8/28
-
GSK's wind turbine plan blows, Scots suggestGlaxoSmithKline's ($GSK) effort to go green at one of its Scottish plants by using wind turbines is facing some ill winds. In the coastal town of Montrose, townspeople want to put the kibosh on GSK's2012/8/27
-
Pfizer severs supply deal with India's ClarisEven as other companies are tightening links with Indian generics makers, Pfizer has killed another marriage, this one with Claris Lifesciences. Pfizer called off a proposed marketing agreement with2012/8/27
-
Indian sales reps strike to demand strict drug-promo rulesIn the U.S., pharma sales reps turn whistleblower when they believe their companies are flouting the rules. In India, they apparently go on strike. According to domestic media reports, about 150,2012/8/24
-
Pfizer figures traditional drug promos are getting oldNo question that the viewing public has grown cynical about drug advertising. Who hasn't mocked the stock-in-trade DTC ad? Its smiling patients and grinning animated figures, backed up by a litany o2012/8/24
-
Ex-rep claims Abbott pushed TriCor off-labelAbbott Laboratories ($ABT) recently wrapped up its Depakote difficulties with the Department of Justice, with a $1.6 billion off-label marketing settlement. Now, we discover that another Abbott ex-e2012/8/23
-
Wockhardt to sell generic copy of Pfizer’s Geodon in IndiaIndia-based drug maker Wockhardt has received tentative approval to market its generic version of Geodon (ziprasidone), an anti-psychotic drug sold in the US by Pfizer. The US Food and Drug Administr2012/8/23